Companies › THPharm
2 active drug programs in 6 registered trials: 4 Phase 3, 1 Phase 2, 1 Phase 1; Cardiovascular, Neurology, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Dapagliflozin (THP-00101) Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 3 | Type 2 Diabetes | Dec 2026 |
| Telmisartan (THP-00102) Type-1 angiotensin II receptor antagonist | AGTR1 | Phase 3 | Type 2 Diabetes; Parkinsons Disease (PD); Ovarian Cancer; Prostate Cancer | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06647745 | Dapagliflozin (THP-00101) | Phase 3 | Type 2 Diabetes | Cardiovascular | Dec 2026 |
| NCT06647745 | Telmisartan (THP-00102) | Phase 3 | Type 2 Diabetes | Cardiovascular | Dec 2026 |
| NCT06647745 | Telmisartan (THP-00102) | Phase 3 | Type 2 Diabetes | Cardiovascular | Dec 2026 |
| NCT06168487 | Telmisartan (THP-00102) | Phase 1 | Prostate Cancer | Oncology | Apr 2027 |
| NCT06815497 | Telmisartan (THP-00102) | Phase 2 | Ovarian Cancer | Oncology | Apr 2027 |
| NCT07207057 | Telmisartan (THP-00102) | Phase 3 | Parkinsons Disease (PD) | Neurology | May 2031 |
Shin Poong Pharmaceutical Shenzhen Ausa Pharmed iVascular S.L.U. CSPC Mingfule Pharmaceutical (Guangzhou) Pulmovant
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.